Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20
03 juin 2024 08h00 HE
|
Indaptus Therapeutics
Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American...
Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting
29 mai 2024 08h00 HE
|
Indaptus Therapeutics
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
08 mai 2024 08h00 HE
|
Indaptus Therapeutics
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer...
Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast cancer
29 mai 2020 02h00 HE
|
Tiziana Life Sciences PLC
StemPrintER Outperforms Oncotype DX in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patientsSPARE Model is up to 40-50% more accurate than standard clinical markers in...
Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to Oncotype DX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the American Society of Clinical Oncology (ASCO) Virtual Conference
14 mai 2020 02h00 HE
|
Tiziana Life Sciences PLC
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA)...
Tiziana Life Sciences to present two studies featuring StemPrintER, a stem cell biology-based Breast Cancer Prognostic Tool during the American Society of Clinical Oncology (ASCO) Virtual Conference
11 mai 2020 02h00 HE
|
Tiziana Life Sciences PLC
NEW YORK and LONDON, May 11, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for...